phosphoglycerate kinase 1
Zuletzt aktualisiert 18. Aug 2020
Erfüllt die redaktionelle Richtlinien
- HerunterladenHerunterladen
- Teilen
- Language
- Diskussion
- Ask Patient
- Audio-Version
- Zu bevorzugten Quellen bei Google hinzufügen
Der PGK1 gene provides instructions for making an enzyme called phosphoglycerate kinase. This enzyme is found in cells and tissues throughout the body, where it is involved in a critical energy-producing process known as glycolysis. During glycolysis, the simple sugar glucose is broken down to produce energy.
Normal function
Der PGK1 gene provides instructions for making an enzyme called phosphoglycerate kinase. This enzyme is found in cells and tissues throughout the body, where it is involved in a critical energy-producing process known as glycolysis. During glycolysis, the simple sugar glucose is broken down to produce energy.
Phosphoglycerate kinase helps carry out a chemical reaction that converts a molecule called 1,3-diphosphoglycerate, which is produced during the breakdown of glucose, to another molecule called 3-phosphoglycerate. This reaction generates one molecule of adenosine triphosphate (ATP), which is the main energy source in cells.
Researchers suspect that phosphoglycerate kinase may have additional functions, although little is known about the other roles this enzyme may play in cells.
Conditions referring to this gene or chromosome
Other names
cell migration-inducing gene 10 protein
MGC117307
MGC142128
MGC8947
MIG10
PGK1_HUMAN
PGKA
primer recognition protein 2
PRP 2
Related patient information and medicines

Patient information leaflet
Glykogenspeicherkrankheiten
Glykogenspeicherkrankheiten are a group of inherited diseases. They result from a problem with one of the proteins (known as enzymes) involved in the conversion of glucose to glycogen, or the breakdown of glycogen back into glucose. They mostly tend to affect your liver and muscles. Most ar... Type II (Pompe's disease). Type VII (Tarui's disease)..

Patient information leaflet
Primärer Leberkrebs
It is not likely to be curative for primary liver cancer but may shrink the tumour down to slow the progression of the disease. There are new medicines being developed for the treatment of liver cancer. For example, sorafenib is a type of medicine called a multi-targeted kinase inhibitor. National Institute for Health and Care Excellence (NICE).

Patient information leaflet
Leberfunktionstests
Leberfunktionstests are a set of blood tests commonly done to check on the health of your liver. Changes in liver function tests give a clue as to whether your liver is under strain, inflamed, infected or diseased, and how badly. The pattern of the liver functio... What does an abnormal ALT (SGPT), AST (SGOT) or creatine kinase level mean. AST.

Patient information leaflet
Duchenne-Muskeldystrophie
The name Duchenne comes von the doctor who first studied this condition. Wie common ist Duchenne muscular dystrophy. About 1 in 3,500 boys in the UK are born with DMD. Gene Therapie The National Institute for Health and Care Excellence (NICE) approved the use of ataluren in 2023. Although this has not been in use for long, it appears that this.

Patient information leaflet
Muskeldystrophie
Muskeldystrophie ist ein inherited (genetic) disorder causing muscle weakness. There are different types of muscular dystrophy, which vary as to how severe they are, ranging from very mild to severe. Also, if a child has delayed motor mil... MD may be diagnosed using one or more of the following tests: A blood test Blood tests for creatine kinase.

Patient information leaflet
Mundkrebs
Diagnosing mouth cancer Your healthcare professional may suspect mouth cancer if you have a lesion in your mouth (such as a sore, an ... Dr Krishna Vakharia , 16th October 2023 The National Institute for Health and Care Excellence (NICE) has recommended that a person should receive a diagnosis or ruling out of cancer within 28 days of being.
Weiterführende Lektüre und Referenzen
- phosphoglycerate kinase 1; MedlinePlus, National Library of Medicine.
- Beutler E. PGK deficiency. Br J Haematol. 2007 Jan;136(1):3-11. doi: 10.1111/j.1365-2141.2006.06351.x.
- Flanagan JM, Rhodes M, Wilson M, Beutler E. The identification of a recurrent phosphoglycerate kinase mutation associated with chronic haemolytic anaemia and neurological dysfunction in a family from USA. Br J Haematol. 2006 Jul;134(2):233-7. doi: 10.1111/j.1365-2141.2006.06143.x. Epub 2006 Jun 1.
- Noel N, Flanagan JM, Ramirez Bajo MJ, Kalko SG, Manu Mdel M, Garcia Fuster JL, Perez de la Ossa P, Carreras J, Beutler E, Vives Corrons JL. Two new phosphoglycerate kinase mutations associated with chronic haemolytic anaemia and neurological dysfunction in two patients from Spain. Br J Haematol. 2006 Feb;132(4):523-9. doi: 10.1111/j.1365-2141.2005.05882.x.
- Spiegel R, Gomez EA, Akman HO, Krishna S, Horovitz Y, DiMauro S. Myopathic form of phosphoglycerate kinase (PGK) deficiency: a new case and pathogenic considerations. Neuromuscul Disord. 2009 Mar;19(3):207-11. doi: 10.1016/j.nmd.2008.12.004. Epub 2009 Jan 20.
- Svaasand EK, Aasly J, Landsem VM, Klungland H. Altered expression of PGK1 in a family with phosphoglycerate kinase deficiency. Muscle Nerve. 2007 Nov;36(5):679-84. doi: 10.1002/mus.20859.
Artikelverlauf
Artikel auch verfügbar in Englisch, Deutsch, Spanisch, Französisch, Italienisch, Portugiesisch, Hindi, Hebräisch, Arabisch, und Schwedisch.
18. Aug 2020 | Neueste Version
1 Dec 2011 | Ursprünglich veröffentlicht
Teilen Sie Ihre Gedanken oder Erfahrungen mit anderen in unserem Patientengemeinschaften.
Abonnieren Sie den Patienten-Newsletter
Ihre wöchentliche Dosis klarer, vertrauenswürdiger Gesundheitsberatung - geschrieben, um Ihnen zu helfen, sich informiert, selbstbewusst und in Kontrolle zu fühlen.
Durch das Abonnieren akzeptieren Sie unsere Datenschutzrichtlinie. Sie können sich jederzeit abmelden. Wir verkaufen Ihre Daten niemals.

